Philippine Health Research Registry
Display Options
Results List
Results 1 - 13 of 13 research(es) registered in March 2016

Show: All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

#
Study
         
Project Status:
Ongoing
Project Description:
The study is a randomized double masked study with the objective to assess the safety and efficacy of abicipar pegol compared with ranibizumab (Lucentis®) in treatment-naïve patients with neovascular age-related macular degeneration (AMD)
Project Status:
Ongoing
Project Description:
Aims to evaluate the cancer chemopreventive activity ofSorghum bicolor ethanolic extract via in vitro cell culture studies.... [read more]
Project Status:
Ongoing
Project Description:
Assesstheanti-thrombocytopenic activity of the formulated papaya and guava leaves capsule which may possibly possess better platelet augmenting action since most of the studies conducted dealt separately with papaya and guava
Project Status:
Pending
Project Description:
This is a multiple dose, randomised, parallel, double blind, double dummy, multicentre and multinational Phase III study to determine the efficacy and safety of Aclidinium bromide/Formoterol fumarate compared with individual components and placebo and Aclidinium bromide compared with Placebo when administered to patients with stable Chronic Obstruc... [read more]
Project Status:
Pending
Project Description:
Study to demonstrate the efficacy (including inhibition of structural damage), safety and tolerability up to 2 years of secukinumab in Active Psoriatic Arthritis
Project Status:
Completed
Project Description:
Phase 3 clinical trial evaluating the safety and immunogenicity of the new formulation of Euvichol®.The study will be conducted in healthy adults and children (1-40) years of age and will be stratified into two age groups, Adults (18-40 years old) and Children (1-17 years old). Approximately a total of 442 participants will be enrolled. Both age g... [read more]
Project Status:
Ongoing
Project Description:
All subjects will receive treatment for up to 52 weeks. The total study period for an individual subject will be up to 56 weeks, including a 2-week Screening Period and 2-week Follow-Up Period. During the study, subjects‟ OCS therapy will be managed according to standard clinical practice; all other existing asthma therapy will remain unchanged, ... [read more]
Project Status:
Completed
Project Description:
Typhoid fever, an invasive bacterial infection caused by Salmonella enterica serovar typhi, remains an important public health problem in the world especially in the impoverished populations of developing countries. Vaccination with Vi polysaccharide has been shown to protect individuals from typhoid fever but Vi vaccine has a number of limitations... [read more]
Project Status:
Pending
Project Description:
There is an urgent need to identify new drugs, especially drugs with activity against persistent organisms that may enable shorter treatment regimens. Carbapenems have activity against TB in vitro and in animal models and there are case reports of apparent activity in patients with TB. Faropenem is an oral penem, closely related to the carbapenem c... [read more]
Project Status:
Ongoing
Project Description:
Project Description:This is a randomized, double-blind, active-controlled, multicenter, parallel-group Phase 3 study of the safety and efficacy of tanezumab when administered by subcutaneous injection for 56 weeks compared to Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in subjects with osteoarthritis of the knee or hip.   In this study, approxi... [read more]
Project Status:
Pending
Project Description:
This is a Phase 3, multicenter, long-term observational study of subjects from tanezumab Study A4091056, A4091057 or A4091058 (regardless of treatment group) who undergo a total knee, hip or shoulder replacement during participation in the study (treatment period or safety follow-up period). If while the subject is participating in this study (A409... [read more]
Project Status:
Ongoing
Project Description:
Healthy subjects between age 9 and 50 year will receive in various schedules of CYD vaccine and placebo administration over a 12-month period. They will be further randomized to receive a single booster vaccination of CYD vaccine at either 12 months or 24 months following the last primary series injection.... [read more]
Project Status:
Pending
Project Description:
Two screening visits, and up to 4 study visits in the first 4 months and thereafter visits every 4 months until the end of the studyBlood samples at each study visit.Urine sample collection at specific visits (3 samples collected over 3 days)Two questionnaires to complete at specific visits. EQ-5D-5L - 2 pages in length and KDQL consists of 36 ques... [read more]